

NCT ID	NCT03475004
Title	Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer
Phase	Phase 2
Date Added	2018-03-23
Location	Colorado, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Pembrolizumab, Bevacizumab, and Binimetinib
Tags	MSS/ MMRp
NCT ID	NCT03626922
Title	Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients
Phase	Phase 1
Date Added	2018-08-13
Location	Florida, United States Illinois, United States Michigan, United States Minnesota, United States Pennsylvania, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Dexamethasone, oxaliplatin, Pembrolizumab, Pemetrexed, Alimta, Eloxatin, Keytruda
Tags	MSS/ MMRp
NCT ID	NCT04991948
Title	Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer
Phase	Phase 1
Date Added	2021-08-05
Location	Florida, United States Belgium
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	CYAD-101, FOLFOX, Pembrolizumab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05239741
Title	Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
Phase	Phase 3
Date Added	2022-02-15
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	5-Fluorouracil, Irinotecan, Leucovorin, oxaliplatin
Tags	MSI-H/ MMRd
NCT ID	NCT02608385
Title	Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors

Phase	Phase 1
Date Added	2015-11-18
Location	Illinois, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	Pembrolizumab
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT06106308
Title	Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
Phase	Phase 2
Date Added	2023-10-30
Location	Arizona, United States Arkansas, United States California, United States Florida, United States Hawaii, United States Indiana, United States Kansas, United States Michigan, United States Minnesota, United States Missouri, United States Nevada, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Wisconsin, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Bevacizumab, FOLFIRI, FOLFOX, Onvansertib
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT03155061
Title	Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors
Phase	Phase 1
Date Added	2017-05-16
Location	Japan
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	ONO-4538, ONO-4578, Opdivo
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT05215574
Title	Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Phase	Phase 1

Date Added	2022-01-31
Location	Arizona, United States California, United States Florida, United States Michigan, United States New York, United States Oklahoma, United States Texas, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	NGM831, NGM831 plus pembrolizumab
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT03476681
Title	Study of NEO-201 in Solid Tumors Expansion Cohorts
Phase	Phase 1, Phase 2
Date Added	2018-03-26
Location	Maryland, United States Virginia, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	NEO-201 in combination with pembrolizumab
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT06034860
Title	Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Phase	Phase 1
Date Added	2023-09-13
Location	California, United States Indiana, United States Missouri, United States New York, United States Virginia, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	MT-8421, Nivolumab, Opdivo
Tags	MSI-H/ MMRd